Tempus pricing

About

Tempus AI (NASDAQ: TEM) is a precision-medicine company that pairs large-scale genomic diagnostics with one of healthcare’s biggest libraries of de-identified multimodal clinical data and a growing suite of oncology AI applications. Founded by Groupon co-founder Eric Lefkofsky in 2015 and headquartered in Chicago, it runs a CLIA/CAP lab that sequences tumor and germline DNA/RNA, then reuses the resulting molecular + clinical data to power pharma research and AI products. The clinical menu spans xT (solid-tumor tissue panel), xF (liquid biopsy / ctDNA), xR (RNA), and xM (minimal-residual-disease monitoring); the FDA-approved companion-diagnostic version, xT CDx, is a 648-gene solid-tumor assay.

Tempus is a public company: it IPO’d in June 2024 at $37/share (ticker TEM, ~$410.7M raised) and reported roughly $700M of revenue in 2024 (~32% growth). It has been aggressively rolling up data and capabilities — acquiring hereditary-testing leader Ambry Genetics for $600M (closed Feb 2025) and digital-pathology pioneer Paige AI for $81.25M (Aug 2025, adding ~7M digitized slides and the Virchow/PRISM foundation models). Its revenue splits into Genomics (per-test sequencing) and Data & services (pharma data licensing + AI apps), the latter reaching record total contract value exceeding $1.1B by end-2025.

For the most current information, visit Tempus. Note: Tempus does not publish a consumer price sheet, and tempus.com is bot-protected (Cloudflare/Vercel checkpoint) — the figures here are second-sourced from CMS filings, press releases and investor materials.

Pricing summary : How Tempus AI’s pricing model works

Tempus has no self-serve plan and no public rate card — it monetizes across three revenue lines, each priced in a fundamentally different way.

1. Genomics — per test, reimbursed (not invoiced). Tempus’s sequencing tests (xT, xF, xR, xM) are ordered by clinicians and billed to payers and Medicare, not sold to a customer at a list price. The FDA-approved xT CDx carries an initial Medicare ADLT rate of $4,500/test (set by CMS effective July 2024, vs $2,923 for the older laboratory-developed-test version); from April 2025 that rate resets to the weighted median of private-payer amounts. What Tempus actually collects is the blended average selling price (ASP) across all payers — about $1,590 in Q1 2025 (up from ~$1,530 in Q4 2024). Third-party reviews cite list prices of roughly $1,500–$3,000/test before insurance.

2. Data & services — custom multi-year contracts. Tempus licenses de-identified multimodal data and builds models for pharma under bespoke, often multi-year agreements (e.g. $200M from AstraZeneca/Pathos over ~3 years). This line reached record total contract value (TCV) >$1.1B by end-2025 across 70+ pharma customers, and is the high-margin engine — data/services gross margin (~77%) roughly doubles genomics (~48%).

3. AI apps — quoted software. Tempus One (generative clinical assistant), Lens (real-world data analytics, with “pay for the data you need” rentals), and Next are sold to providers and life-sciences customers as quoted enterprise software.

What makes this different: unlike the token- and seat-metered AI tools elsewhere in this corpus, Tempus’s primary meter is the diagnostic test — a clinical act reimbursed by a third-party payer, so the “price” is a reimbursement rate and a blended ASP, not a number a buyer chooses. Layered on top is a data-licensing business whose unit is a custom pharma contract measured in TCV, not per-unit pricing.

Pricing by product

Sales motions across products: clinicians order tests (reimbursement handled with payers/Medicare); pharma data and AI-app deals are sales-led and custom-contracted. No free tier, no self-serve, no monthly card checkout. Genomics figures are CMS/Medicare reimbursement and reported ASP; data figures are disclosed deal/TCV values — all second-sourced, not a posted rate card.

Hidden costs : What Tempus AI users actually pay

Tempus’s “hidden cost” is really a gap between sticker and collected: a headline Medicare rate of $4,500/test for xT CDx sits far above the ~$1,590 blended ASP Tempus actually realizes, because most volume is reimbursed at lower negotiated commercial-payer rates, and some claims are denied or partially paid. For a provider, the real economics are about coverage and prior authorization, not a list price — a patient may owe little out of pocket if covered, or face balance-billing exposure if not.

Other things to budget for: on the pharma side, deals bundle data access, data rentals, and milestone-based model-development fees — the $200M AstraZeneca/Pathos figure is a contract value realized over ~3 years, not an upfront payment, so revenue recognition lags signing. An estimated $200 ASP uplift is expected from 2027 as the tumor-only xT CDx FDA approval migrates the DNA portfolio to unified ADLT pricing. And because two acquisitions (Ambry, Paige) were folded in during 2025, year-over-year per-test and mix comparisons are noisy.

Want to estimate your own Tempus AI bill? Use the Tempus pricing calculator to model your costs based on test volume and payer mix.

Pricing evolution : Tempus AI pricing history and changes

Cadence

Tracked range: 2024–present (Tempus has only been public since June 2024). Tempus publishes no posted rate card, so there are no Wayback price snapshots — the evolution here is reimbursement and corporate, driven by CMS rate decisions, IPO disclosure, and acquisitions rather than list-price changes.

Notable changes

• 2024-06 — IPO at $37/share on Nasdaq (TEM), ~$410.7M raised; ASP and pharma TCV become public disclosures.
• 2024-07 — CMS sets the xT CDx Medicare ADLT rate at $4,500/test (vs $2,923 LDT), effective through March 2025, then resetting to the weighted median of private-payer amounts.
• 2025-02 — Closes the $600M Ambry Genetics acquisition ($375M cash + $225M stock), adding a large hereditary-testing per-test business.
• 2025-04 — $200M AstraZeneca/Pathos data-and-model deal — flagship of the high-margin data line.
• 2025-08 — Acquires Paige AI for $81.25M, adding ~7M pathology slides and Virchow/PRISM foundation models.
• 2025-12 — Record TCV >$1.1B; data & application revenue ~$316M for FY2025.

What’s unique : Tempus AI’s distinctive pricing mechanics

1. The meter is a reimbursed diagnostic, not a chosen price. Tempus’s primary unit is the test, but the buyer (a clinician) never sees a price — the test is billed to a payer or Medicare, so “pricing” is a reimbursement rate ($4,500 ADLT for xT CDx) and a blended ASP (~$1,590). Revenue is gated by coverage and prior authorization, not a rate card.

2. Data is the high-margin product the tests create. Every sequenced test feeds a de-identified multimodal dataset that Tempus licenses to pharma under custom multi-year contracts (>$1.1B TCV). At ~77% gross margin versus ~48% for genomics, the data flywheel is where the profit pools — the diagnostics line is partly a data-acquisition engine.

3. Acquire the data moat, don’t price it. Rather than monetize incrementally, Tempus buys complementary data assets — Ambry ($600M, hereditary testing) and Paige ($81.25M, ~7M pathology slides + foundation models) — turning M&A into a pricing-power strategy: more modalities make the licensed dataset more valuable to pharma.

Strengths & weaknesses

Billing UX : Tempus AI billing controls and transparency

• Billing controls — There is no in-app plan picker. Genomics billing flows through the payer/Medicare claims process (the lab bills insurers; patients may receive an EOB and any patient-responsibility balance, often softened by patient-assistance programs). Data and AI-app engagements are negotiated enterprise contracts managed by account teams.
• Usage visibility — Providers receive structured molecular reports and can access results/AI insights via Tempus One and provider portals; pharma customers analyze licensed data in Lens. But there is no public cost calculator or rate card — neither a provider nor a pharma buyer can model spend without a coverage check or a sales conversation.
• Payment options — Genomics: third-party payer reimbursement and patient billing. Data/AI apps: invoiced multi-year enterprise contracts, often with data-access, rental, and milestone components. As a public company, the aggregate of all this surfaces as Genomics and Data & services revenue lines in quarterly filings.

Strategic wins : Why Tempus AI’s pricing decisions worked

1. Pricing on a reimbursed clinical act

Anchoring genomics on the test lets Tempus plug into existing oncology reimbursement rails, and the FDA-approved xT CDx unlocks a premium $4,500 ADLT rate that unregulated tools can’t command — converting regulatory clearance into pricing power. See choosing the right usage metric.

2. A data flywheel with two revenue engines

Every sequenced test enriches a de-identified multimodal dataset that Tempus then licenses to pharma at ~77% margin (>$1.1B TCV) — the same asset monetized twice, with the high-margin data line subsidizing the capital-intensive diagnostics business. Related: how AI companies structure pricing.

3. M&A as pricing strategy

Buying Ambry ($600M) and Paige ($81.25M) widened the modalities (hereditary genetics, pathology slides, foundation models) inside the licensable dataset — making each pharma contract worth more without changing a posted price. See outcome-based pricing trends.

Areas to improve : Gaps in Tempus AI’s pricing approach

1. Reimbursement opacity

Because revenue depends on payer coverage and a blended ASP far below the headline rate, neither providers nor investors can easily predict realized per-test economics. Clearer published ASP-by-test and coverage detail would reduce the guesswork. See bill shock and cost unpredictability.

2. Sticker-vs-collected gap

The $4,500 ADLT headline versus ~$1,590 collected is a wide spread that invites confusion and balance-billing risk for uncovered patients. A transparent patient-responsibility and assistance-program story would reduce friction at the point of care.

3. Mix complexity after acquisitions

Folding in Ambry and Paige mid-2025 muddies per-test and margin trends. Cleaner segment disclosure (legacy oncology vs hereditary vs data) would let the market price the business on its true unit economics rather than blended noise.

Key takeaways

1. Tempus has no price sheet — it has three revenue lines. Genomics is reimbursed per test, data is licensed under custom multi-year pharma contracts, and AI apps are quoted software.
2. The genomics “price” is a reimbursement rate and a blended ASP. xT CDx carries a $4,500 Medicare ADLT rate, but Tempus collects a blended oncology ASP of about $1,590 (Q1 2025).
3. Data licensing is the high-margin engine. Record TCV >$1.1B by end-2025, ~$316M FY2025 data revenue, ~77% gross margin (vs ~48% for genomics), including a $200M AstraZeneca/Pathos deal.
4. M&A is a pricing strategy. Ambry ($600M) and Paige ($81.25M) widened the licensable dataset, raising the value of pharma contracts without a posted price.
5. Public-company transparency, not consumer transparency. Since the June 2024 IPO ($37/share) the model is legible to investors via ASP and TCV — but a provider or patient still can’t look up a price.

UBP implications

1. A reimbursed clinical event can be the usage meter. Tempus bills per test, but the test is a payer-reimbursed diagnostic — showing usage-based pricing can attach to regulated clinical acts, where the “rate” is set by CMS and payers rather than the vendor. See usage-based pricing strategy.
2. Usage can be a data-acquisition strategy. When each metered unit also produces a licensable data asset, a low-margin usage line can fund a high-margin data line — a model any data-rich vendor should study.
3. Custom TCV is the “price” for data. For pharma data licensing, the unit isn’t per-record — it’s a multi-year contract measured in total contract value, a reminder that some usage-based businesses monetize via bespoke commitments, not published per-unit rates. See choosing the right usage metric.

Sources

• Tempus Oncology (providers / genomic tests) — bot-protected (accessed 2026-06-10)
• Tempus Life Sciences (data & services) — bot-protected (accessed 2026-06-10)
• Tempus Lens — real-world multimodal data — bot-protected (accessed 2026-06-10)
• CMS Awards Tempus ADLT Status for xT CDx ($4,500 initial rate) — second-source pricing (accessed 2026-06-10)
• Why Tempus AI (TEM) Stock Is Rising — $4,500 xT CDx rate (Benzinga) — second-source (accessed 2026-06-10)
• Tempus Announces Pricing of IPO ($37/share, ~$410.7M) (accessed 2026-06-10)
• Tempus Q3 2024 Results & Ambry Acquisition ($600M) — second-source (accessed 2026-06-10)
• AstraZeneca enters $200m AI cancer pact with Tempus and Pathos — second-source (accessed 2026-06-10)
• Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion (accessed 2026-06-10)
• Tempus AI acquires Paige for $81.25M (Aug 2025) (accessed 2026-06-10)

Bottom line

Tempus AI (NASDAQ: TEM) is a public precision-medicine platform that monetizes across three revenue lines rather than a price sheet: genomics — per-test sequencing (xT/xF/xR/xM) reimbursed by payers and Medicare (xT CDx carries a $4,500 initial ADLT rate, but the blended oncology ASP is about $1,590); data & services — custom multi-year licensing of de-identified multimodal data to pharma, a high-margin engine that hit record TCV >$1.1B by end-2025 (including a $200M AstraZeneca/Pathos deal); and AI apps (Tempus One, Lens, Next). It IPO’d at $37/share in June 2024 and bolted on Ambry ($600M) and Paige ($81.25M) to deepen its data moat. The distinctive mechanic: the meter is a reimbursed diagnostic that also manufactures the licensable data Tempus sells at ~77% margin. Browse the pricing blueprint for more fully-researched company profiles.

Want to compare Tempus AI against other healthcare and AI-platform companies, like the digital-pathology firm Paige AI it acquired? Browse the pricing blueprint.